Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage

Thorax. 2018 Apr;73(4):308-310. doi: 10.1136/thoraxjnl-2017-211135. Epub 2018 Feb 2.

Authors

Kai-Feng Xu¹, Xinlun Tian¹, Yanli Yang¹, Hongbing Zhang²

Affiliations

¹ Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
² Department of Physiology, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 29438097
DOI: 10.1136/thoraxjnl-2017-211135

No abstract available

Keywords: lymphangioleiomyomatosis; rapamycin; sirolimus.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunosuppressive Agents
Lung Neoplasms
Lymphangioleiomyomatosis*
Sirolimus*

Substances

Immunosuppressive Agents
Sirolimus